ZTS enters the final stretch of May with a clear internal vs. external disconnect. Three directors stepped in to buy shares at post-earnings lows in mid-May — yet the Street spent the same weeks racing to slash price targets.
The insider activity is the most striking data point this week. After the stock collapsed 25.5% on May 7 — one of the sharpest single-day drops the name has seen — the company's own boardroom opened its wallet. Independent Chairman Michael McCallister bought 3,000 shares at $77.76 on May 11. Two weeks later, Frank Damelio added 6,650 shares at $75.39, and Paul Bisaro purchased 2,000 at $75.88. Combined, the three directors deployed roughly $886,000 in open-market purchases across a ten-day window. Net insider buying over the past 90 days is approximately $957,000 on a gross basis. These are not trivial awards or option exercises — they are cash purchases by senior fiduciaries at prices not seen since before the stock became a market darling. That kind of cluster buying tends to reflect a conviction that the sell-off was overdone rather than a structural inflection.
The Street is telling a different story. Analyst activity has been uniformly negative since the earnings shock. Argus Research downgraded to Hold this week, becoming the most recent in a string of moves that have seen targets fall sharply across the board. Stifel lowered its target to $95 from $105 on May 22. Citigroup, which only initiated coverage in April with a $145 Buy, cut that target to $112 just five weeks later. JPMorgan — one of the more bullish voices — trimmed from $190 to $130 while keeping Overweight. The overall consensus has slid to Hold, with 8 Buys against 9 Holds. The mean target implies material upside from the current $80.23 handle, but given the velocity of cuts, the degree of conviction behind those targets is debatable. Bulls point to ZTS's dominant market share in animal health and a deep companion-animal pipeline; bears flag premium valuation, competition in pet dermatology, and what was a deeply disappointing earnings print.
The valuation reset is significant. The P/E multiple has compressed by roughly 5 points over the past 30 days to around 11.3x. Price-to-book has fallen by 2.8 turns to 8.1x. Even after that re-rating, the stock is not obviously cheap in absolute terms — though the EV/EBITDA reading of 9.3x and a quality factor score that sits near the top of the sector (the most recent stock-score note pegged quality at 82.6, supported by a Piotroski F-score of 7) suggest the underlying business has not deteriorated with the share price. Momentum, by contrast, is deeply negative: the stock is down 31% over the past month and is trading roughly 39% below its 52-week high of $131.10.
Positioning in the lending market is notably relaxed. Short interest has actually been unwinding — it peaked near 4% of the float in mid-April and has eased to 3.2% now, down about 18% over the past month. Borrow costs dropped sharply this week to 0.37%, about a third of their level from just a few sessions ago, and availability is extraordinarily wide at over 4,600% of outstanding short interest. That means roughly 230 million shares are available to borrow against a current short position of only about 13.4 million. The borrow market is under no meaningful pressure whatsoever. Options, meanwhile, are running below their recent defensive posture — the put/call ratio eased to 0.42, nearly one standard deviation below its 20-day average of 0.51. That's a mild shift toward calls relative to the cautious tone that dominated in late April and early May.
The next scheduled earnings date is August 5. What to watch between now and then is whether the director buying cluster marks a credible floor — or whether continued analyst target compression and any deterioration in companion animal market data reopens the gap between fundamental conviction and price action.
See the live data behind this article on ORTEX.
Open ZTS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
